Form 4: Cingulate Inc. EVP and CSO Raul R. Silva Granted Stock Options

Raul R. Silva, EVP and CSO of Cingulate Inc., was granted stock options for 63,324 shares on June 11, 2024, following stockholder approval of an amendment to the company's equity incentive plan.

Summary

• Raul R. Silva, the EVP and CSO of Cingulate Inc., received a stock option grant on June 11, 2024.
• The grant is for 63,324 shares of Cingulate Inc. common stock.
• The exercise price of the options is $1.18 per share.
• The grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, contingent on stockholder approval of Amendment No. 1 to the 2021 Omnibus Equity Incentive Plan.
• Stockholder approval was obtained on June 11, 2024.
• The options vest 50% on the six-month anniversary of the grant date, with the remaining shares vesting in substantially equal monthly installments over the subsequent 30-month period.
• The options expire on March 4, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating a positive alignment of interests between management and shareholders. The sentiment is moderately positive as it suggests confidence in the executive's future contributions.

Positives

• The grant of stock options aligns the interests of the EVP and CSO with those of the shareholders.
• The vesting schedule incentivizes long-term performance and retention.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with those of the shareholders. This is a standard compensation tool used to attract and retain talent.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are generally determined based on industry benchmarks and company-specific performance goals.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
• Employees may see this as a positive sign of investment in leadership.

Key Dates

Keywords

stock options, Cingulate Inc., Raul R. Silva, EVP, CSO, equity incentive plan, stockholder approval, vesting